Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.66 +0.02 (+0.10%)
Streaming Delayed Price Updated: 2:13 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,755,875
Open 25.65
Bid (Size) 25.66 (103)
Ask (Size) 25.67 (81)
Prev. Close 25.64
Today's Range 25.59 - 25.83
52wk Range 25.20 - 40.37
Shares Outstanding 5,606,688,356
Dividend Yield 6.39%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 Safe Haven Stocks That Can Withstand the Market’s Worst Meltdowns
Safe haven stocks offer stability even during market fall in communication, financials, healthcare, energy and consumer staples. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga

Performance

YTD
-13.67%
-13.67%
1 Month
-7.41%
-7.41%
3 Month
-6.60%
-6.60%
6 Month
-15.99%
-15.99%
1 Year
-34.54%
-34.54%

More News

Read More
Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings
Via Benzinga
Exposures COVID-19
(PFE) - Analyzing Pfizer's Short Interest
Via Benzinga
5 Top Stocks to Buy in May
Via The Motley Fool
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Pfizer's Options: A Look at What the Big Money is Thinking
Via Benzinga
Why I'm Buying This Beaten-Down, High-Yield Dividend Stock Hand Over Fist
Via The Motley Fool
Forget Nvidia: Prominent Billionaires Are Selling It and Buying These 2 Ultra-High-Yield Dividend Stocks Instead
Via The Motley Fool
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
mRNA Is Promising A Breakthrough In Fighting Cancer
Via Benzinga
Exposures COVID-19
3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole
Via The Motley Fool
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
From Pfizer Inc.
Via Business Wire
3 Dividend Stocks to Buy on the Dip: April 2024
Via InvestorPlace
Is Viking Therapeutics Incredibly Undervalued?
Via The Motley Fool
3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street
Via The Motley Fool
3 Dividend Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
7 Dividend Stocks to Buy Now for Steady Returns in Any Market
Via InvestorPlace
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Via Benzinga
Exposures Product Safety
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
Via The Motley Fool
Pfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
Via Investor's Business Daily
Exposures Product Safety
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
From Pfizer Inc.
Via Business Wire
What's Going On With Pfizer Stock On Thursday?
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.